TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02658903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxys Catheter
Description: The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Covidien Mona-Therm Foley catheter
Description: The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
Study: NCT03478930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
Study: NCT04644484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN023
Description: The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rabies Immune Globulin (HRIG)
Description: The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
Study: NCT03390517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography with indocianyne green
Description: The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
Study: NCT04644484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
Study: NCT01770041

Intervention type: OTHER
Intervention: Paracetamol (observation of routine administration)
Description: Normal administration of paracetamol as prescribed by operating surgeon
Study: NCT04095468

Intervention type: RADIATION
Intervention: Preoperative Radio(Chemo)Therapy
Description: Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
Study: NCT03478930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
Study: NCT01416064

Intervention type: DRUG
Group type: OTHER
Intervention: Molindone
Description: The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
Study: NCT00885846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qigong therapy
Description: For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training
Description: For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
Study: NCT03425877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Band 2
Description: Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Band 2
Description: Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Band 2
Description: Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
Study: NCT00578669

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: Once daily for 16 weeks
Study: NCT01327144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
Study: NCT01606397

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally (capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally (capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally (capsule)
Study: NCT01327144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciclovir
Description: Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
Study: NCT03009916

Intervention type: DRUG
Group type: OTHER
Intervention: cholestagel® (Colesevelam)
Description: 3750mg

Intervention type: DRUG
Group type: OTHER
Intervention: cholestagel® (Colesevelam)
Description: 3750mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: 3750mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: 3750mg
Study: NCT04340609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
Study: NCT00613535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical debridement
Description: Mechanical shaver will be used to remove large chondral flaps and loose fragments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paragon T2
Description: Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lavage debridement
Description: Remove loose chondral fragments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF- based Debridement
Description: Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
Study: NCT02994940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: already included in arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: already included in arm/group descriptions
Study: NCT04438226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical approach
Description: The surgical approach of hemiarthroplasty after femoral neck fracture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical approach
Description: The surgical approach of hemiarthroplasty after femoral neck fracture
Study: NCT02032706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deliver therapy when the supine position is detected
Description: Application of vibrotactile feedback to the neck when the supine position is detected
Study: NCT03275818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
Study: NCT04754971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-education program
Description: Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
Study: NCT01715363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracile
Study: NCT01998672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Px-102
Description: Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drinking solution
Study: NCT03425877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Task
Description: The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task
Description: This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
Study: NCT01094184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
Study: NCT03580369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial
Study: NCT03296384

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and environmental evaluation
Description: For schizophrenic's patients, specific assessment will be perform

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and environmental evaluation
Description: For schizophrenic's patients, specific assessment will be perform
Study: NCT01352130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Intravenous Ondansetron 8 mgs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: Intravenous Granisetron 1 mgs
Study: NCT03580369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Lyophilized powder for solution in vial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid in vial
Study: NCT04307511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin
Study: NCT01837927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: Once daily for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Respimat®
Description: Once daily for 52 weeks
Study: NCT06276036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identification of specific markers
Description: Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
Study: NCT01606397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally (capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally (capsule)
Study: NCT01960829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT02816437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpenBiome Fecal Microbiota Transplantation retention enema
Description: Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
Study: NCT00802867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
Description: 0.5 mL, Intramuscular
Study: NCT03614819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser group
Description: Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Sealing Group
Description: Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
Study: NCT00309257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE I, ATA II and Statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril, Valsartan and Fluvastatin
Description: Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate.
Study: NCT04218604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized atrial fibrillation ablation
Description: Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
Study: NCT04467164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)
Description: Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)
Description: Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
Study: NCT02562950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 500 mg
Description: Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 1000 mg
Description: Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
Study: NCT01951885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Patients will receive Mycophenolate beginning on day +1. Patients \>40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (low dose)
Description: MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.